Our findings highlight GGPP‐mediated YAP activation as a novel mechanism of crizotinib resistance and provide a rationale that targeting YAP may be a potential treatment strategy for EML4‐ALK‐positive NSCLC patients who have acquired resistance to ALK‐TKIs. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.